BioNTech at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
BioNTech brings 3 presentations to IDWeek 2026 in Washington. Its program centres on mRNA vaccines in development against mpox and herpes, plus COVID vaccination. Its studies report safety and immune responses for an investigational mpox vaccine and a trivalent vaccine candidate against genital herpes.
| Organization | IDWeek 2026 Attendance |
|---|---|
BioNTech Mainz, Germany | |
German mRNA company that co-developed the Comirnaty COVID-19 vaccine with Pfizer and is testing vaccines for mpox and genital herpes. | Talk Thu Oct 22 4:15pm–4:27pm A Phase 2a Study of Safety and Exploratory Immune Responses to BNT166a, an Investigational mRNA Mpox Vaccine VaccinesHIV, sexually transmitted infections and viral hepatitis Talk Fri Oct 23 11:06am–11:18am Safety and Immunogenicity of BNT163, a Trivalent mRNA HSV-2 Vaccine Candidate for Genital Herpes Ulcer Disease VaccinesHIV, sexually transmitted infections and viral hepatitis Industry Fri Oct 23 11:15am–12:00pm Sticking it to COVID-19: Updates on the Disease and a Vaccine Option from BioNTech and Pfizer VaccinesRespiratory infections and COVID-19 |
Instantly find 20 buyers from BioNTech
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction